Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity by Hegi, M E et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2008
Correlation of O6-methylguanine methyltransferase (MGMT)
promoter methylation with clinical outcomes in glioblastoma and
clinical strategies to modulate MGMT activity
Hegi, M E; Liu, L; Herman, J G; Stupp, R; Wick, W; Weller, M; Mehta, M P; Gilbert,
M R
Hegi, M E; Liu, L; Herman, J G; Stupp, R; Wick, W; Weller, M; Mehta, M P; Gilbert, M R (2008). Correlation of
O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and
clinical strategies to modulate MGMT activity. Journal of Clinical Oncology : Official Journal of the American
Society of Clinical Oncology, 26(25):4189-4199.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 2008,
26(25):4189-4199.
Hegi, M E; Liu, L; Herman, J G; Stupp, R; Wick, W; Weller, M; Mehta, M P; Gilbert, M R (2008). Correlation of
O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and
clinical strategies to modulate MGMT activity. Journal of Clinical Oncology : Official Journal of the American
Society of Clinical Oncology, 26(25):4189-4199.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 2008,
26(25):4189-4199.
Correlation of O6-methylguanine methyltransferase (MGMT)
promoter methylation with clinical outcomes in glioblastoma and
clinical strategies to modulate MGMT activity
Abstract
Resistance to alkylating agents via direct DNA repair by O(6)-methylguanine methyltransferase
(MGMT) remains a significant barrier to the successful treatment of patients with malignant glioma.
The relative expression of MGMT in the tumor may determine response to alkylating agents, and
epigenetic silencing of the MGMT gene by promoter methylation plays an important role in regulating
MGMT expression in gliomas. MGMT promoter methylation is correlated with improved
progression-free and overall survival in patients treated with alkylating agents. Strategies to overcome
MGMT-mediated chemoresistance are being actively investigated. These include treatment with
nontoxic pseudosubstrate inhibitors of MGMT, such as O(6)-benzylguanine, or RNA
interference-mediated gene silencing of MGMT. However, systemic application of MGMT inhibitors is
limited by an increase in hematologic toxicity. Another strategy is to deplete MGMT activity in tumor
tissue using a dose-dense temozolomide schedule. These alternative schedules are well tolerated;
however, it remains unclear whether they are more effective than the standard dosing regimen or
whether they effectively deplete MGMT activity in tumor tissue. Of note, not all patients with
glioblastoma having MGMT promoter methylation respond to alkylating agents, and even those who
respond will inevitably experience relapse. Herein we review the data supporting MGMT as a major
mechanism of chemotherapy resistance in malignant gliomas and describe ongoing studies that are
testing resistance-modulating strategies.
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ABSTRACT 
 
Resistance to alkylating agents via direct DNA repair by O6-methylguanine methyltransferase 
(MGMT) remains a significant barrier to the successful treatment of patients with malignant 
glioma. The relative expression of MGMT in the tumor may determine response to alkylating 
agents, and epigenetic silencing of the MGMT gene by promoter methylation plays an important 
role in regulating MGMT expression in gliomas. MGMT promoter methylation correlates with 
improved progression-free and overall survival in patients treated with alkylating agents. 
Strategies to overcome MGMT-mediated chemoresistance are being actively investigated. 
These include treatment with nontoxic pseudo-substrate inhibitors of MGMT, such as  
O6-benzylguanine, or RNA interference-mediated gene silencing of MGMT. However, systemic 
application of MGMT inhibitors is limited by an increase in hematologic toxicity. Another strategy 
is to deplete MGMT activity in tumor tissue using a dose-dense temozolomide schedule. These 
alternative schedules are well tolerated; however, it remains unclear whether they are more 
effective than the standard dosing regimen or whether they effectively deplete MGMT activity in 
tumor tissue. Of note, not all glioblastoma patients with MGMT promoter methylation respond to 
alkylating agents, and even those who respond will inevitably relapse. Herein we review the 
data supporting MGMT as a major mechanism of chemotherapy resistance in malignant gliomas 
and describe ongoing studies that are testing resistance-modulating strategies.  
 
Key words: O6-methylguanine methyltransferase, temozolomide, tumor resistance, glioma, 
alkylating agents, glioblastoma 
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INTRODUCTION 
 
Alkylating agents, including the chloroethylnitrosoureas (carmustine [BCNU], lomustine [CCNU], 
and fotemustine), procarbazine, and temozolomide, are commonly used to treat malignant brain 
tumors. These agents cause DNA damage by adding alkyl groups to DNA, which triggers DNA 
repair, thereby inducing apoptosis. Temozolomide is a methylating agent that modifies the DNA 
at several sites, most commonly N7-methylguanine and N3-methyladenine, which constitute 
nearly 90% of the total methylation events.1 However, these adducts are efficiently repaired by 
the base excision repair pathway and have a low cytotoxic potential. Only 5% to 10% of the 
methylation events mediated by temozolomide yield O6-methylguanine, but if the methyl group 
is not removed before cell division, these adducts trigger the DNA mismatch repair (MMR) 
pathway and are highly cytotoxic.2  
O6-methylguanine methyltransferase (MGMT) is a cellular DNA repair protein that 
rapidly reverses alkylation (including methylation) at the O6 position of guanine,3 thereby 
neutralizing the cytotoxic effects of alkylating agents such as temozolomide. The protective 
effect of MGMT activity against the cytotoxic effects of alkylating agents has been demonstrated 
in human cell lines, xenograft models, and MGMT transgenic mice.4-9 High levels of MGMT 
activity in tumor tissue are associated with resistance to alkylating agents.7 In contrast, 
epigenetic silencing of the MGMT gene by promoter methylation results in decreased MGMT 
expression in tumor cells.10,11 Methylation of the MGMT promoter has been observed in a 
variety of tumor types,12 which is consistent with the observation that epigenetic “silencing” of 
genes is a common mechanism for inactivating tumor suppressor genes during malignant 
progression.13,14 Herein, we review the role of MGMT in conferring resistance to alkylating 
agents and strategies to modulate MGMT activity in malignant gliomas.  
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THE ROLE OF MGMT IN RESISTANCE TO ALKYLATING CHEMOTHERAPY 
 
O6-methylguanine methyltransferase is ubiquitously expressed in normal human tissues.15 Most 
of our knowledge about MGMT as a DNA repair protein is based on observations following 
exposure to alkylating agents.5 In several ways, the MGMT-mediated repair process (Fig 1) is 
unique and differs from other DNA repair pathways; MGMT is not part of a repair complex but 
acts alone. It specifically removes the methyl group from the O6 position of guanine, thereby 
restoring the nucleotide to its native form without causing any DNA strand breaks, and it is a 
“suicide enzyme.” On transfer of the alkyl group to an internal cysteine residue in the active site 
of MGMT, the enzyme is irreversibly inactivated, thus requiring de novo protein synthesis to 
maintain enzyme activity. In fact, the process is saturable; an excess of O6-methylguanine in the 
DNA can deplete MGMT. Although the O6 position of guanine is not the most common target of 
alkylating agents, the resulting promutagenic lesions act as an important trigger for cytotoxicity 
and apoptosis.16 Left unrepaired, this modified guanine preferentially pairs with thymine during 
DNA replication, which activates the MMR pathway. However, MMR only targets and corrects 
the newly synthesized daughter strand, leaving behind the O6-methylguanine in the template 
strand. It has been hypothesized that the MMR pathway, in an attempt to repair this mismatch, 
undergoes reiterative cycles of resynthesis and attempted repair (ie, futile cycling). This results 
in DNA double-strand breaks, thereby activating apoptotic pathways leading to cell death.17,18 
The essential role of the MMR pathway is illustrated by studies showing that cells deficient in 
both MGMT and the MMR pathway are 100 times more resistant to methylating agents.19 It has 
also recently been shown that treatment of glioblastoma (GBM) with temozolomide seems to 
select for inactivation of MMR as a result of mutation or loss of expression of the MMR-
associated protein MSH6.20 Consequently, the highest therapeutic activity of alkylating agents is 
expected in tumor cells with low levels of MGMT and an intact MMR system.5 Given the central 
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role of MGMT in resistance to alkylating agents and its unique properties, MGMT is an ideal 
potential target for biochemical modulation of drug resistance.21-23 
 
Analytic Determination of MGMT 
Several methods for measuring MGMT levels within tumors have been described. The 
MGMT protein can be detected in tissue samples by immunohistochemistry,24 enzyme activity 
can be measured by high-performance liquid chromatography (HPLC),25,26 and epigenetic 
silencing of the MGMT gene by promoter methylation can be assessed using a methylation-
specific polymerase chain reaction assay (MSP).27,28 Determination of MGMT activity by HPLC 
requires fresh tissue and is most suitable for quantitative studies in pure populations of cells.25,26 
Immunohistochemical analysis has revealed heterogeneous MGMT expression patterns within 
tumors, often with regions of intense staining bounded by adjacent cells that lack 
expression.24,29,30 Tumor-infiltrating lymphocytes, microglia, and blood vessels may also express 
high levels of MGMT protein (Fig 2). Both HPLC and immunohistochemistry have been used to 
study the correlation between MGMT activity and drug resistance in cell lines and xenografts 
derived from a variety of human tumors.31 These studies have shown that MGMT expression 
varies widely in different tumor types and cell lines.  
The MSP assay has been developed for determining the MGMT methylation status of 
CpG islands in the gene promoter (Fig 3).28,32 The MSP assay detects CpG island methylation 
with high sensitivity and specificity. This assay requires only small quantities of DNA and can be 
performed on DNA extracted from paraffin-embedded tissue samples; however, fixation may 
cause deterioration of the DNA. Therefore, best results are obtained with cryopreserved tumor 
specimens.  
For diagnostic purposes in patients with glioma, one advantage of the MSP assay lies in 
the fact that detection of the methylated MGMT allele can be attributed solely to neoplastic 
cells.33 Therefore, nontumor tissue contamination of the surgical specimen does not interfere 
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with the result. Furthermore, MGMT gene expression may be induced in tumor cells in response 
to DNA damage from alkylating agents or radiotherapy (RT) and also by corticosteroids,6,34 
although this remains to be demonstrated in primary gliomas. Aberrant methylation of CpGs is a 
heritable change in the DNA that may be less susceptible to treatment-induced alterations. 
Recent reports have reviewed and discussed the different techniques for assessing MGMT and 
whether they can predict clinical outcome in glioma patients.35-37 The correlation with outcome 
was variable throughout the studies analyzed, regardless of the techniques employed; however, 
the overall interpretation of these results is limited because much of the data come from small 
series or cohorts of mixed glioma subtypes, use of different cut-offs (eg, for 
immunohistochemistry), and heterogeneity of treatment or complete lack of treatment 
information. The latter is highly relevant, since MGMT status is thought to predict benefit 
primarily from treatment with alkylating agents.32,38 Clearly, the methods useful for diagnostic 
purposes will have to be standardized and validated in prospective studies.39,40 
 
MGMT Expression/Methylation and Clinical Outcome in Malignant Glioma 
Clinical studies have correlated MGMT expression or MGMT promoter methylation with 
response to chloroethylnitrosoureas and methylating agents and with survival.41-46 A Southwest 
Oncology Group study found that MGMT expression levels in newly diagnosed malignant 
astrocytoma assessed by quantitative immunofluorescence were inversely correlated with tumor 
response and survival in patients treated with BCNU.43 The difference in median survival among 
patients with tumors showing high (n = 41) versus low (n = 23) MGMT expression levels was 
significant (8 versus 29 months, respectively; P = .0002; Fig 4).43 In a retrospective analysis of 
47 glioma patients treated with whole-brain RT and various alkylating agents, Esteller et al42 
demonstrated an improved clinical outcome in the presence of a methylated MGMT promoter. 
Similarly, in a phase II trial, we demonstrated significantly improved clinical outcome in patients 
with newly diagnosed GBM who had a methylated MGMT promoter and were treated with 
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temozolomide and RT.47 The 18-month survival rate was 62% among patients with a methylated 
MGMT promoter compared with only 8% in the absence of promoter methylation (P = .002). 
These studies identified MGMT promoter methylation status as a potential independent 
prognostic factor for survival in GBM patients treated with alkylating agents. Furthermore, Paz et 
al44 showed that MGMT promoter methylation was associated with a higher rate of clinical 
response in patients with primary glioma treated with temozolomide or other alkylating agents  
(Table 1). However, this association was not observed when patients were treated with 
alkylating agents at relapse, suggesting that selection for treatment resistance had occurred.44  
More recently, MGMT promoter methylation was analyzed in tissue samples from 
patients with newly diagnosed GBM treated within an international, randomized phase III trial 
(European Organization for Research and Treatment of Cancer [EORTC] trial 26981-22981 and 
National Cancer Institute of Canada [NCIC] trial CE.3) comparing RT alone with RT plus 
concomitant and adjuvant temozolomide.32 Paraffin-embedded tissue samples were available 
for 307 (54%) patients. High-quality DNA, allowing for analysis by MSP assay, could be 
extracted from two thirds of the available tissue, and 45% of this group were shown to have a 
methylated MGMT promoter. The MSP assay consisted of a 2-stage polymerase chain reaction 
using nested primers.48 The results showed that MGMT promoter methylation was associated 
with improved overall survival in patients treated with RT plus temozolomide but not in patients 
initially treated with RT alone (Fig 5).32 Among patients whose tumors contained a methylated 
MGMT promoter, patients treated with RT plus temozolomide had a median survival of 21.7 
months compared with 15.3 months for patients assigned to RT alone. In patients treated with 
initial RT alone, MGMT promoter methylation was also associated with a slight improvement in 
survival among patients surviving beyond 9 months. This was expected because more than 
70% of the patients in the RT arm received chemotherapy (most likely with an alkylating agent) 
at progression, and 60% of these patients received temozolomide at progression. When 
progression-free survival (PFS) was analyzed, thereby eliminating second-line therapy as a 
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confounding factor, PFS was only prolonged in patients with a methylated MGMT promoter who 
were treated with RT plus temozolomide (Fig 6).32 In patients with a methylated MGMT 
promoter, median PFS was 10.3 months for patients treated with RT plus temozolomide 
compared with 5.9 months in the RT-only group (P = .001).  
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CLINICAL STUDIES OF TEMOZOLOMIDE AND MGMT INHIBITORS 
 
Given the important role of MGMT in tumor resistance to alkylating agents, a variety of MGMT 
inhibitors have been investigated with the goal of modulating chemoresistance (reviewed by 
McMurry49). O6-benzylguanine (O6-BG) is a potent MGMT-inactivating agent that has been 
studied in combination with alkylating agents. It inactivates MGMT stoichiometrically.50 
However, O6-BG lowers MGMT levels in normal cells as well, increasing toxicity from 
chemotherapy. A dose-escalation study was conducted to determine the dose of O6-BG that 
would effectively suppress MGMT activity in anaplastic gliomas.51 Escalating doses of O6-BG 
were administered 6 or 18 hours before tumor resection, and MGMT activity was measured in 
snap-frozen tumor tissue. A dose of 120 mg/m2 given 6 hours before surgery inhibited MGMT 
activity in > 90% of patients, whereas MGMT activity was inhibited in only 45% of patients who 
received O6-BG 18 hours before surgery (Table 2). Although this analysis did not take into 
account that MGMT activity may have been constitutively low due to promoter methylation in 
30% to 50% of patients, these data suggest either that O6-BG is only able to transiently inhibit 
the enzyme or that resynthesis of MGMT can occur rapidly in tumor tissue.51 No toxic side 
effects were observed in this study. Importantly, this study illustrated how transient the reduction 
in MGMT activity may be with such a treatment approach.  
Other studies have attempted to determine the maximum tolerated dose of 
chemotherapy that can be administered in combination with O6-BG. One study showed that 
120 mg/m2 of O6-BG inhibited MGMT activity to undetectable levels for up to 18 hours in the 
tumor, and O6-BG either alone or in combination with 13 mg/m2 BCNU resulted in no serious 
side effects.26 However, in a subsequent phase I study, 100 mg/m2 of O6-BG increased 
hematologic toxicity when used in conjunction with escalating doses of BCNU (13.5, 27, 40, and 
55 mg/m2).52 At the highest dose of BCNU (55 mg/m2), grade 3/4 thrombocytopenia and 
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neutropenia became dose limiting. The maximum tolerated dose of BCNU in combination with 
100 mg/m2 O6-BG was 40 mg/m2 administered at 6-week intervals. In the following phase II trial, 
18 patients with recurrent or progressive nitrosourea-resistant malignant gliomas were treated 
with O6-BG and BCNU.53 No objective tumor responses were observed, but 5 patients had 
stable disease for 6 to 18 weeks. Again, 66% of the patients experienced grade 3/4 
thrombocytopenia and neutropenia. These studies did not stratify patients based on the MGMT 
methylation status of their tumors.  
O6-(4-bromothenyl)guanine (lomeguatrib, PaTrin-2; KuDOS Pharmaceuticals, 
Cambridge, UK) is similar to O6-BG. Preclinical data demonstrated that lomeguatrib sensitized 
an ovarian tumor cell line to temozolomide,54 and the combination of lomeguatrib and 
temozolomide significantly improved inhibition of tumor growth in human melanoma 
xenografts.55 Lomeguatrib is also an oral agent and could be conveniently combined with 
temozolomide. No data on inhibition of MGMT in the tumor or any safety data on the 
combination of lomeguatrib and temozolomide are yet available. 
Furthermore, 2-amino-O4-benzylpteridine derivatives are in preclinical studies and have 
greater tumor specificity,56,57 which could counter the problem of hematologic toxicity associated 
with systemic application of other MGMT inhibitors. The cytotoxicity of BCNU in combination 
with O4-benzylfolates appears to be a function of the R-folate receptor, which is overexpressed 
in many tumor types.57 The compound O4-benzylfolic acid, which has the added advantage of 
greater water solubility, was shown to be 30 times more effective than O6-BG and was effective 
against the mutant P140K-MGMT that is resistant to O6-BG. Thus, this class of compounds may 
have greater clinical potential.  
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Temozolomide and MGMT Depletion: Alternative Dosing Schedules 
It is important to note that alkylating agents themselves are also powerful MGMT-
depleting agents because of their capacity to induce DNA damage. MGMT depletion in the 
tumor could potentially be achieved with alternative dosing schedules of temozolomide that 
deliver more prolonged exposure and higher cumulative doses than the standard 5-day regimen 
(150 to 200 mg/m2/day for 5 days every 28-day cycle).58 Both compressed and extended 
temozolomide schedules have been tested preclinically and clinically. Early results suggested 
that continuous daily administration was more effective than a single dose,59 and more frequent 
administration (ie, twice daily or every 4 hours) yielded the most effective depletion of MGMT 
activity and the highest levels of O6-methylguanine DNA adducts in tumor tissue.60,61 These 
studies suggested that tumor cells become sensitized to temozolomide as MGMT is depleted, 
resulting in greater cytotoxicity with subsequent doses. However, normal hematopoietic cells 
can also become sensitized. For example, in a phase II trial in 30 patients with metastatic 
melanoma who received 5 doses of temozolomide (200 mg/m2 every 4 hours) within 16 hours 
(total dose = 1,000 mg/m2), 68% of patients developed grade 3/4 thrombocytopenia and 54% 
developed grade 3/4 leukopenia, but the compressed dosing schedule did not appear to 
significantly enhance antitumor activity.62 Notably, pretreatment MGMT levels in peripheral 
blood mononuclear cells (PBMCs) correlated with the dose intensity that patients were able to 
tolerate. Profound lymphopenia has also been reported in patients receiving extended daily 
treatment with temozolomide at a dose of 75 mg/m2, which can lead to opportunistic infections 
such as Pneumocystis carinii pneumonia.63-65 
Subsequent clinical trials with temozolomide have explored a variety of dosing 
schedules (Table 3) with the intention of maximizing MGMT depletion in tumor cells. The first 
alternative regimen tested was the extended daily regimen,58 which was subsequently used in 
combination with RT in the trials conducted by the EORTC. These regimens increase exposure 
to temozolomide over a 28-day cycle by approximately 1.5- to 2-fold compared with the 
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standard 5-day regimen, and the hope is that these alternative regimens will increase antitumor 
activity compared with the 5-day regimen without dramatically increasing hematologic toxicity. 
However, to date, there is no empiric evidence that this can be achieved in clinical practice.  
This concept of enhanced MGMT depletion with alternative temozolomide dosing 
regimens has been rigorously tested by Tolcher et al.66 Patients received temozolomide at 
various doses and on 2 alternative dosing schedules: either 7 consecutive days of every 14 
days (7 days on/7 days off) or 21 consecutive days of every 28 days (21/28-day schedule). 
Serial blood samples were taken to assess MGMT enzyme activity in PBMCs. This study 
demonstrated a time- and dose-dependent decrease in MGMT activity with both regimens. 
Continuous dosing for 7 days at a dose of 75 to 175 mg/m2 produced a rapid reduction from 
mean baseline MGMT activity (72% on day 8), which appeared to be fairly dose dependent. 
However, during the 7-day rest period, there was recovery of MGMT activity to approximately 
55% of baseline (Fig 7).66 The 21-day continuous schedule at a lower daily dose (85 to 125 
mg/m2) resulted in a similar reduction (~70%) in mean MGMT activity by day 15, which was 
sustained through day 21.  
This study established a benchmark against which to evaluate alternative dosing 
regimens and illustrated several important concepts with regard to MGMT depletion with 
temozolomide. The depletion of MGMT activity was a function of both the total cumulative dose 
and the area under the concentration time curve.66 The daily and cumulative doses 
administered using a variety of dose-dense regimens are shown in Table 3. Higher doses of 
temozolomide appear to deplete MGMT levels in PBMCs more rapidly than lower doses. 
Administration of temozolomide for 21 consecutive days at a daily dose that resulted in a 
comparable cumulative dose per cycle as the 7-days-on/7-days-off regimen resulted in 
comparable depletion of MGMT activity at lower daily doses. However, this regimen appears to 
achieve more protracted MGMT depletion at least in PBMCs. On the other hand, the 7-days-
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on/7-days-off regimen allows for better recovery of MGMT in PBMCs, which may result in less 
hematologic toxicity.  
Currently, it is not known which of these schedules is more effective at depleting MGMT 
in tumor cells or which will strike a better balance between antitumor activity and hematologic 
toxicity. Although the Tolcher study provides the best rationale for protracted temozolomide 
schedules, there remain a number of important unanswered questions. In particular, it remains 
unknown how these schedules affect MGMT activity in brain tumor tissue. Studies reported by 
Spiro et al26,61 suggest that depletion of MGMT activity in PBMCs occurs at lower doses of  
O6-BG or temozolomide and is not a reliable predictor of MGMT depletion in tumor tissue.  
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BRAIN TUMOR TRIALS WITH NOVEL SCHEDULES OF TEMOZOLOMIDE 
 
A number of studies in patients with high-grade glioma have investigated alternative 
temozolomide dosing schedules and have begun to look at important clinical questions with 
regard to the best treatment strategy in both the first-line and recurrent settings (Table 4).67-74 
One particularly relevant question is whether concomitant RT plus temozolomide is 
sufficient to confer a survival benefit in patients with newly diagnosed GBM. This question is the 
object of an ongoing international Intergroup trial designed to establish the optimal sequence 
and relative contribution of the concomitant and adjuvant chemotherapy compared with RT 
alone in patients with anaplastic astrocytoma. Over 700 patients will be randomized in the 
CATNON trial (Concurrent and Adjuvant Temozolomide in NON-deleted anaplastic 
astrocytoma).  
One study in Greece has examined whether dose intensification of the maintenance 
regimen affects clinical outcome. In a randomized multicenter phase II trial patients with newly 
diagnosed GBM received the standard regimen of concomitant RT plus temozolomide followed 
by temozolomide at a dose of 150 mg/m2 x 5 days every other week compared with RT alone.67 
The results suggested that this dose-intensified maintenance regimen may improve PFS in the 
absence of significant hematologic toxicity.67 Patients treated with RT plus temozolomide had a 
median PFS of nearly 11 months, and 37% of patients had not yet progressed at 1 year. This 
was substantially better than the PFS achieved with RT plus temozolomide in the EORTC/NCIC 
trial (median of 7 months, and 1-year PFS of 27%).75 However, this improvement in PFS did not 
appear to translate into a substantial improvement in overall survival; median overall survival 
was 13.4 months with RT plus temozolomide (compared with 14.6 months in the EORTC/NCIC 
trial75) and only 7.7 months in the RT-only arm.67 Although patient selection cannot be ruled out, 
the poor survival outcome, particularly in the control arm, may have been due to the small 
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number of patients who received chemotherapy at recurrence. Nevertheless, this trial provides 
evidence of the safety and feasibility of a dose-intensified temozolomide maintenance regimen.  
A French phase II study also examined the effect of the 7-days-on/7-days-off regimen 
(150 mg/m2/day) as both neoadjuvant therapy before RT for up to 4 cycles  
(8 weeks) and adjuvant (ie, maintenance) therapy after RT until progression (up to 8 cycles) in 
patients with inoperable tumors.76 This study provided information about antitumor activity in the 
neoadjuvant setting, although the median number of cycles was only 3 (range, 1 to 8). 
Consistent with the previous attempts at neoadjuvant therapy for GBM, 25% of patients had a 
partial response, and 31% had stable disease. Median PFS in this group of patients with poor 
prognosis was 3.8 months, and median overall survival was 6 months. Hematologic toxicity 
requires careful monitoring; 24% of patients developed grade 3 or 4 thrombocytopenia, 14% 
had grade 4 granulocytopenia, and 14% had grade 4 lymphopenia. In addition, 5 patients 
developed interstitial pneumopathy, and 6 patients required dose reductions. This study also 
provided evidence that MGMT expression correlated with response to temozolomide; despite 
dose intensification, patients with high levels of MGMT expression in their tumor tissue were 
unlikely to respond and more likely to progress early.  
To date, the largest clinical experience with an alternative temozolomide regimen in the 
first-line setting is from the joint German-Swiss randomized phase III trial of the Neuro-oncology 
Working Group within the German Cancer Society (NOA-08).71 This trial is currently 
investigating the benefit of temozolomide (100 mg/m2 7 days on/7 days off) versus RT alone as 
a primary therapy for high-grade glioma until treatment failure and shall enroll 340 patients over 
the age of 65 years.  
In the recurrent setting, several studies have investigated dose-dense regimens. Italian 
investigators studying temozolomide at 75 mg/m2 on a 21/28-day schedule reported grade 3 
lymphocytopenia in one fourth of patients and an increased incidence of infections.72,77 In our 
previous experience with temozolomide administered at 75 mg/m2 for 6-7 weeks concurrent with 
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RT, up to 80% of patients developed profound lymphocytopenia, further promoted by the 
frequent administration of corticosteroids at diagnosis.63 A small Belgian phase II trial has also 
examined the 21/28-day schedule at a dose of 100 mg/m2 in 19 patients with recurrent 
anaplastic astrocytoma and anaplastic oligoastrocytoma.73 A report on the safety profile of this 
regimen indicated a high incidence of grade 3 and 4 lymphopenia in 10 and 9 patients, 
respectively. In addition, there were 2 suspected opportunistic infections: 1 herpes zoster 
reactivation during lymphopenia and 1 case of Pneumocystis carinii pneumonia after the patient 
had discontinued study treatment. Therefore, it appears that regular lymphocyte counts and 
prophylaxis against opportunistic infections may be required when using this regimen, 
particularly in the recurrent setting. Similar observations have been made in melanoma patients 
who were treated with the daily schedule (75 mg/m2 × 6 to 7 weeks).64 The high frequency of 
lymphopenia in patients receiving prolonged daily schedules of temozolomide raises the 
question whether more intermittent dosing might be better tolerated. The most compelling data 
come from a German study in 39 patients with recurrent GBM who were treated with 150 mg/m2 
on the 7-days-on/7-days-off regimen, which was associated with a relatively low incidence of 
lymphopenia.69,70 This regimen produced an overall response rate of 9.5%, a 6-months PFS rate 
of 48%, and a median PFS of 21 weeks (~5 months),69 which is superior to the data reported on 
the standard 5-day dosing regimen.78 These data have since been confirmed and extended.74 
Importantly, in the more recent trial involving 90 patients, there was no significant difference in 
median PFS between patients with a methylated or unmethylated MGMT promoter at initial 
diagnosis.74 This suggests either that patients with a methylated MGMT promoter at diagnosis 
acquired resistance to temozolomide during progression20,44 or that this regimen may indeed 
overcome MGMT-mediated resistance, thereby extending time to progression in patients with 
an unmethylated promoter.  
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
A variety of molecular markers may have prognostic value in patients with malignant 
glioma. These markers include high expression of MGMT, overexpression of the epidermal 
growth factor receptor (EGFR), presence of the EGFRvIII mutation, expression of the YKL-40 
gene, tenascin expression, loss or mutation of the PTEN gene, loss of chromosome 10, and 
mutation or loss of the p53 gene.79-82 Although MGMT expression appears to have a strong 
influence on response to alkylating agents and clinical outcome in patients with GBM, to date 
none of these markers, including MGMT, has been definitively confirmed.  
An international group of investigators from the United States, Canada, and Europe is 
collaborating on a successor clinical trial to the EORTC/NCIC study. This trial, RTOG 0525, led 
by the Radiation Therapy Oncology Group Intergroup (RTOG) along with the EORTC and the 
North Central Cancer Treatment Group, will test whether increasing the dose intensity of 
adjuvant temozolomide will improve survival compared with the standard regimen established 
by the EORTC/NCIC study.83,84 The study design is shown in Fig 8.83,84 The underlying 
hypothesis for this phase III trial is based on the laboratory finding that prolonged exposure of 
tumor cells to temozolomide results in reduced MGMT activity.85 An accrual of 1,153 patients is 
expected, and both clinical and molecular markers are being used to assign patients to the two 
treatment arms. Clinical factors include the validated subgroups identified by the recursive 
partitioning analysis of the RTOG, and patients in classes III, IV, and V are eligible for study 
entry. In addition, immediate tumor tissue sample submission is mandatory to prospectively 
assess MGMT promoter methylation status (using a quantitative MSP assay), and patients are 
then stratified by MGMT promoter methylation status before randomization. This will ensure a 
balanced number of patients with MGMT-methylated tumors assigned to the control and 
experimental arms, which will be critical for validation of MGMT promoter methylation as a 
molecular marker of response and/or prognosis.  
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While differences in MGMT promoter methylation may determine the clinical course in 
GBM patients treated with temozolomide, it is presently not recommended to use the MGMT 
promoter methylation assay to determine who should receive temozolomide and who should 
not.37 First, an independent confirmation of the retrospective analysis from the EORTC/NCIC 
trial is necessary. Second, there is reason to believe that alternative dose-intensified schedules 
may overcome resistance in patients with an unmethylated MGMT promoter.86 Third, allocating 
GBM patients to specific treatments on the basis of MGMT promoter methylation status will only 
assume clinical relevance when effective alternative treatments become available. At present, 
the only established alternative is nitrosourea-based chemotherapy, which is also subject to 
resistance mediated by MGMT.  
A promising strategy to overcome resistance mediated by MGMT appears to be 
depletion of MGMT by prolonged exposure to low doses of alkylating agents. For these agents, 
the feasibility of intensified dosing schedules has been demonstrated. Optimizing this approach 
in conjunction with modulation of dosing schedules is of paramount importance to maximize the 
clinical effectiveness of temozolomide. However, myelosuppression continues to be dose-
limiting when MGMT depletion is maximized by dose intensification or the addition of MGMT 
inhibitors such as O6-BG. The development of tumor-specific MGMT inhibitors may overcome 
this limitation. This is an area of intense ongoing research, which will hopefully result in further 
improvements in clinical outcomes.  
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TABLES 
 
Table 1. Clinical Response to First-Line Alkylating Agent Chemotherapy in Glioma Patients 
According to Methylation Status 
MGMT Unmethylated MGMT Methylated 
First-Line 
Chemotherapy 
Total. 
Patients, n 
Patients, 
n 
Positive 
Response, 
n (%) 
Patients, 
n 
Positive 
Response, 
n (%) P  
Temozolomide 40 28 7 (25) 12 8 (68) .030 
BCNU 35 24 4 (17) 11 6 (55) .041 
Procarbazine/CCNU 17 12 1 (8) 5 3 (60) .043 
All drugs 92 64 12 (19) 28 17 (61) .001 
Abbreviations: MGMT, O6-methylguanine-methyltransferase; BCNU, carmustine; CCNU, lomustine. 
Reprinted with permission from Paz et al.44 
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Table 2. Rapid Reconstitution of MGMT Activity in Brain Tumor Tissue After Effective Depletion 
by O6-Benzylguanine 
O6-BG dose, 
mg/m2 
No. of 
Evaluable 
Patients 
Hours From O6-BG Dose to 
Tumor Resection 
No. of Patients With 
Undetectable MGMT 
Activity* (%) 
40 5 6 2 (40) 
60 8 6 4 (50) 
80 15 6 9 (60) 
100 8 6 5 (63) 
120 18 6 17 (94) 
120 11 18 5 (45) 
Abbreviations: MGMT, O6-methylguanine-methyltransferase; O6-BG, O6-benzylguanine.  
*< 10 fmol/mg protein.  
Reprinted with permission from Schold et al.51 
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Table 3. Alternative Temozolomide Dosing Schedules 
Regimen 
Daily Dose, 
mg/m2 Schedule 
Dose Intensity, 
mg/m2 Per 28-
Day Cycle 
Relative Dose 
Intensity 
5/28 days 200 5 days every 28 days 1,000 1 
Daily 75 Daily × 6 to 7 weeks, 
every 10 weeks 
1,470 1.5 
Daily  50 Daily continuously 1,400 1.4 
10/28 days 150 Day 1 to 5 and 15 to 19 
every 28 days 
1,500 1.5 
14/28 days 150 - 175 7 days on/7 days off 2,100 - 2,450 2.1 - 2.5 
21/28 days 100 21 days on/7 days off 2,100 2.1 
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Table 4. Clinical Studies of Alternative Temozolomide Dosing Regimens in Primary Brain Tumors 
Study 
Patient 
Population Schedule 
Median 
PFS, 
Months 
 
Median OS, 
Months 
Athanassiou67 
(N = 110) 
Newly dx GBM RT + 75 mg/m2 TMZ concomitant 
150 mg/m2 days 1 to 5, 15 to 19 
q28 days 
v RT alone (60 Gy) 
10.8 
 
 
5.2 
13.4 
 
 
7.7 
Chinot68 
(N = 30) 
Inoperable GBM 150 mg/m2 7 days on/7 days off as 
neoadjuvant tx before RT and 
maintenance after RT 
3.8 
(6-month 
PFS = 21%) 
6 
Wick69,70 
(N = 39) 
Recurrent GBM 150 mg/m2 7 days on/7 days off 5 
(6-month 
PFS = 48%) 
 
NOA-08*71 
 
Newly dx  
AA or GBM  
> 65 years old 
100 mg/m2 7 days on/7 days off  
v RT alone  
NA NA 
Tosoni72 
(N = 51) 
 
Glioma  
 
75 mg/m2 21/28 days NA NA 
Neyns73  
(N = 19) 
Recurrent AA & 
AO 
100 mg/m2 21/28 days 6-month 
PFS = 56% 
12.9 
Wick74 
(n = 90) 
Recurrent 
glioma 
150 mg/m2† 7 days on/7 days off 5.5  
(6-month 
PFS = 44%) 
8.8 
Abbreviations: PFS, progression-free survival; OS, overall survival; dx, diagnosed; GBM, glioblastoma; RT, radiotherapy; 
TMZ, temozolomide; tx, treatment; NOA, Neuro-Oncology Working Group of the German Cancer Society; AA, anaplastic 
astrocytoma; NA, not available; AO, anaplastic oligoastrocytoma.  
*This phase III trial expects to enroll 340 patients in up to 30 German and Swiss centers. 
†with individual dose adjustments according to hematologic toxicity 
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FIGURE LEGENDS 
 
Fig 1. The DNA repair process mediated by O6-methylguanine DNA methyltransferase (MGMT). 
The MGMT enzyme transfers the methyl group from the O6-methylguanine DNA adduct to a 
cysteine residue in the enzyme and becomes irreversibly inactivated.  
 
Fig 2. O6-methylguanine-methyltransferase (MGMT) expression in glioblastoma (GBM). (A) 
Small cells within the GBM, which may or may not be of tumor origin, express MGMT. (B) 
Glioblastoma displaying high levels of MGMT expression in most tumor cells. (C and D) Blood 
vessels expressing MGMT, here shown in vascular proliferations. Higher magnifications are 
shown below. The GBM tissue microarray is described in by Godard et al.87 
 
Fig 3. Methylation-specific polymerase chain reaction (PCR) assay. PCR product indicating a 
methylated O6-methylguanine-methyltransferase (MGMT) promoter is shown by arrows. 
Abbreviations: U, unmethylated MGMT promoter; M, methylated MGMT promoter; L, 100-bp 
DNA marker ladder; Meth PBL, enzymatically methylated DNA from peripheral blood 
lymphocytes. Reprinted with permission from Hegi et al.32 Copyright © 2005 Massachusetts 
Medical Society. All rights reserved.  
 
 
Fig 4. Kaplan-Meier estimate of survival among patients with tumors showing high versus low 
O6-methylguanine-methyltransferase (MGMT) expression levels who were treated with 
carmustine. Reprinted with permission from the American Society of Clinical Oncology.43  
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Fig 5. Kaplan-Meier analysis of overall survival based on O6-methylguanine-methyltransferase 
(MGMT) promoter methylation status (unmethylated [Unmeth] v methylated [Meth]) and random 
assignment to radiotherapy (RT) plus temozolomide (TMZ) or RT alone. Reprinted with 
permission from Hegi et al.32 Copyright © 2005 Massachusetts Medical Society. All rights 
reserved.  
 
Fig 6. Kaplan-Meier estimation of progression-free survival according to randomization and O6-
methylguanine-methyltransferase promoter methylation status of the tumors. Abbreviations: 
Meth, methylated; Unmeth, unmethylated; TMZ, temozolomide; RT, radiotherapy. Reprinted 
with permission from Hegi et al.32 Copyright © 2005 Massachusetts Medical Society. All rights 
reserved.  
 
Fig 7. Levels of O6-methylguanine-methyltransferase (MGMT) enzyme activity in peripheral 
blood mononuclear cells at baseline and after treatment with the temozolomide 7-days-on/7-
days-off schedule at 75 to 175 mg/m2/day (A) or the 21/28-day schedule at 85 to 125 mg/m2/day 
(B). Reprinted with permission from Tolcher et al.66  
 
Fig 8. Study schema for the ongoing Radiation Therapy Oncology Group Intergroup trial. 
MGMT, O6-methylguanine-methyltransferase; RPA, recursive partitioning analysis; RT, 
radiotherapy; TMZ, temozolomide. *Dosing will be initiated at 75 mg/m2 in cycle 1 with dose 
escalation to 100 mg/m2 in subsequent cycles if no dose-limiting hematologic toxicity occurs. 
Data from the National Cancer Institute83 and the European Organisation for Research and 
Treatment of Cancer.84 
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